Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amarpal Sahai"'
Autor:
Aram Oganesian, Monica M. Mita, Amarpal Sahai, Sanjeev Redkar, Michael S. Gordon, Lee S. Rosen, Pietro Taverna, Nirmal Kapoor, Anthony W. Tolcher, Mohammad Azab, Robert G. Bristow, Gavin Choy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:195-204
Amuvatinib is an oral multi-kinase inhibitor that suppresses RAD51, inhibits mutant c-KIT and platelet-derived growth factor receptor alpha, and has synergistic activity with DNA-damaging agents and topoisomerase inhibitors such as etoposide, doxorub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5e027fc3a400f01be8a93da67d72fa
https://doi.org/10.1007/s00280-014-2481-1
https://doi.org/10.1007/s00280-014-2481-1
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 33:171-178
This study evaluates a storage-phosphor imaging system for rapid autoradiography and quantitation of beta- and gamma-ray emitters in mice. Known quantities of authentic 3H, 14C, and 195mPt (0.06 to 31,714 DPM/mm2) were exposed to imaging plates of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a294cb33b7ae32e96cc47633d32b3e84
https://doi.org/10.1016/1056-8719(94)00089-m
https://doi.org/10.1016/1056-8719(94)00089-m
Autor:
Raoul Tibes, Mohammad Azab, Sanjeev Redkar, Aram Oganesian, Anthony W. Tolcher, Gavin Choy, Amarpal Sahai, Pietro Taverna, Gil Fine
Publikováno v:
Cancer chemotherapy and pharmacology. 71(2)
Amuvatinib is a novel orally administered tyrosine kinase inhibitor with in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51. Amuvatinib was investigated in a first-in-human, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06a6306287257b442567dfcb333002a
https://pubmed.ncbi.nlm.nih.gov/23178951
https://pubmed.ncbi.nlm.nih.gov/23178951
Autor:
Aram Oganesian, Gavin Choy, Amarpal Sahai, Scott Rasmussen, Mohammad Azab, Joanne Collier, James Kissling, Rajashree Joshi-Hangal, Gil Fine, Sanjeev Redkar
Publikováno v:
Cancer chemotherapy and pharmacology. 70(1)
Amuvatinib is a multi-targeted tyrosine kinase inhibitor with activity that also disrupts DNA damage repair through suppression of homologous recombination protein Rad51. Amuvatinib dry-powder capsules (DPC) showed evidence of activity in early Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34805c3da4ef5039150cb751e433cbde
https://pubmed.ncbi.nlm.nih.gov/22349808
https://pubmed.ncbi.nlm.nih.gov/22349808
Autor:
Gavin Choy, Saiama N. Waqar, Goetz H. Kloecker, Mojtaba Noursalehi, Amarpal Sahai, Nancy Cecchettini, Leora Horn, D. Ross Camidge, Jitendra Gandhi, Pietro Taverna, Taofeek K. Owonikoko, Mohammad Azab, Maciej Krzakowski, Lauren Averett Byers
Publikováno v:
Cancer Research. 73:2095-2095
Background: Amuvatinib is an oral multi-targeted TKI of c-Kit and PDGFRα and modulates DNA repair by down regulation of Rad51. Rad51 is a key protein in the homologous recombination repair pathway for DNA double strand breaks which can mediate resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a3047af78458747b47b982fcc70a26
https://doi.org/10.1158/1538-7445.am2013-2095
https://doi.org/10.1158/1538-7445.am2013-2095